Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human LRP5 Anticorps:
anti-Mouse (Murine) LRP5 Anticorps:
anti-Rat (Rattus) LRP5 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Monoclonal LRP5 Primary Antibody pour FACS, ELISA - ABIN969535
Urano, Shiraki, Usui, Sasaki, Ouchi, Inoue: A1330V variant of the low-density lipoprotein receptor-related protein 5 (LRP5) gene decreases Wnt signaling and affects the total body bone mineral density in Japanese women. dans Endocrine journal 2009
Show all 2 Pubmed References
Human Polyclonal LRP5 Primary Antibody pour WB - ABIN127323
Del Valle-Pérez, Arqués, Vinyoles, de Herreros, Duñach: Coordinated action of CK1 isoforms in canonical Wnt signaling. dans Molecular and cellular biology 2011
Show all 2 Pubmed References
Human Monoclonal LRP5 Primary Antibody pour ELISA, WB - ABIN517568
Kim, Goel, Alexander: Differentiation generates paracrine cell pairs that maintain basaloid mouse mammary tumors: proof of concept. dans PLoS ONE 2011
Human Monoclonal LRP5 Primary Antibody pour ELISA, WB - ABIN561692
Badders, Goel, Clark, Klos, Kim, Bafico, Lindvall, Williams, Alexander: The Wnt receptor, Lrp5, is expressed by mouse mammary stem cells and is required to maintain the basal lineage. dans PLoS ONE 2009
The extracellular domains of Lrp5/6 behave as physiologically relevant inhibitors of noncanonical Wnt (Montrer WNT2 Anticorps) signaling during Xenopus and mouse development in vivo.
Data show that in zebrafish, lrp5 also controls cell migration during early morphogenetic processes and contributes to shaping the craniofacial skeleton.
LRP5 (rs556442) had a significant influence on trigylceride (TG) levels in unadjusted analysis and when adjusted for interacting factors. Higher TG levels were observed in AA/AG genotype of rs566442 in comparison to GG genotype (OR = 2.028, 95% CI = 0.997-4.127, p = 0.049).
The detection rate for mutations in the three known genes was 23%. Mutations in LRP5 and TSPAN12 (Montrer TSPAN12 Anticorps) were more frequent, accounting for 10% and 8%
To our knowledge, these are the first two cases of the syndrome described in Italy. Genetic testing proved to be fundamental for definition of the syndrome and confirms the importance of early detection of LRP5 variants for management of systemic features of the disease in patients and carrier relatives.
VAP1 cleaved the extracellular region of LRP5. This cle (Montrer AOC3 Anticorps)avage removes four inhibitory beta-propeller structures, resulting in activation of LRP5/6.
Among the detected mutations, LRP5 accounted for the largest proportion with a mean mutation rate of 16.1% (5/31, 16.1%), followed by NDP (Montrer NDP Anticorps) (3/31, 9.7%), FZD4 (Montrer FZD4 Anticorps) (2/31, 6.5%), TSPAN12 (Montrer TSPAN12 Anticorps) (1/31, 3.2%), and KIF11 (Montrer KIF11 Anticorps) (1/31, 3.2%). All the novel changes were predicted to be pathogenic by a series of bioinformatics analyses.
wild-type and all five mutant LRP5 proteins were assayed for the ability to activate the Norrin (Montrer NDP Anticorps)/beta-catenin (Montrer CTNNB1 Anticorps) pathway by established luciferase reporter assays, and all mutants failed to activate the pathway.
findings revealed an unrecognized role of Caprin-2 (Montrer CAPRIN2 Anticorps) in facilitating LRP5/6 constitutive phosphorylation at G2/M through forming a quaternary complex with CDK14 (Montrer CDK14 Anticorps), Cyclin Y (Montrer CCNY Anticorps), and LRP5/6.
This study did not identify LRP5 polymorphisms as a risk factor for osteoporosis in Thai menopausal women.
We identified four novel LRP5 missense mutations in these FEVR (Montrer NDP Anticorps) families: c.C1042T (p.R348W), c.G1141A (p.D381N), c.C1870T (p.R624W), and c.A4550G (p.Y1517C). All four of these LRP5 mutations led to significant reduction of enzymatic activity with response to NORRIN (Montrer NDP Anticorps). Our findings expand the mutational spectrum of FEVR (Montrer NDP Anticorps) in the Indian population and provide some guidelines in clinical diagnosis.
In this study, the splice site mutation c.2827thorn1G > A found in LRP5 (603506) gene is thought to cause microphthalmia in this family.
The phenotype of the Lrp5(tvrm111B) mutant includes abnormalities of the retinal vasculature and of bone mineral density.
the LRP5 mutation in high bone mass transgenic mice shows altered bone matrix composition
Lrp6 (Montrer LRP6 Anticorps) is the key mediator of Wnt3a (Montrer WNT3A Anticorps) signaling in osteoblasts and Lrp5 played a less significant role in mediating Wnt3a (Montrer WNT3A Anticorps) signaling.
Identification of a link between Wnt (Montrer WNT2 Anticorps)-Lrp5 signaling and insulin (Montrer INS Anticorps) signaling in the osteoblast that has the potential to influence energy balance and compound the detrimental effects of a HFD on whole-body metabolism.
Lrp5(-/-) mice displayed significantly delayed retinal vascular development, absence of deep layer retinal vessels, leading to increased levels of vascular endothelial growth factor and subsequent pathologic glomeruloid vessels, as well as decreased inner retinal visual function.
A mouse LRP5 ectodomain recombinant was cleaved by VAP1 (Montrer AOC3 Anticorps), creating a peptide, VAHLTGIHAVEE, detected by mass spectrometric analysis of the 140-kDa fragment, suggesting that the sessile bond by VAP1 (Montrer AOC3 Anticorps) is Glu1206-Val1207.
we revealed miR (Montrer MLXIP Anticorps)-375-3p negatively regulated osteogenesis by targeting LRP5 and beta-catenin (Montrer CTNNB1 Anticorps)
lung myeloid cells are responsive to Lrp5/beta-catenin (Montrer CTNNB1 Anticorps) signaling, leading to differentiation of an alveolar macrophage subtype that antagonizes the resolution of lung fibrosis.
LRP5 is a novel anti-inflammatory macrophage marker that positively regulates migration, phagocytosis, lipid uptake and metabolism.
These results revealed a new role of the canonical Lrp5/6-beta-catenin (Montrer CTNNB1 Anticorps) pathway in regulating the morphogenesis of the cerebellum during postnatal development.
This gene encodes a transmembrane low-density lipoprotein receptor that binds and internalizes ligands in the process of receptor-mediated endocytosis. This protein also acts as a co-receptor with Frizzled protein family members for transducing signals by Wnt proteins and was originally cloned on the basis of its association with type 1 diabetes mellitus in humans. This protein plays a key role in skeletal homeostasis and many bone density related diseases are caused by mutations in this gene. Mutations in this gene also cause familial exudative vitreoretinopathy.
Lipoprotein Receptor Related Protein 5
, low density lipoprotein receptor-related protein 5
, low-density lipoprotein receptor-related protein 5
, low-density lipoprotein receptor-related protein 5-like
, low density lipoprotein receptor-related protein 7
, low-density lipoprotein receptor-related protein 7